An interventional study of The dynamics of airway resistance and conventional suctioning in Mechanical Ventilation Pressure High, Ventilator-Associated Pneumonia (VAP) and Respiratory Depression Neonatal, sponsored by Affiliated Hospital of Nantong University. Recruiting at 3 sites in China. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-29.
Sponsored by Affiliated Hospital of Nantong University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Pneumonia, Ventilator-Associated with a site in China — 10 open to participants now, 11 under way, none of them phase 3. Pneumonia, Ventilator-Associated · China.
Among the 26 studies in Pneumonia, Ventilator-Associated with a site in China, this one is the 6th largest by planned enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2025, is one of 6 with no phase, reaches primary completion later than 10 of the 10 other live ones, and was the 23rd registered.
420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.
Browse Pneumonia, Ventilator-Associated studies →10 of the 26 studies in Pneumonia, Ventilator-Associated with a site in China are open now. Recruiting first, the newest first:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18+
Sir Run Run Shaw Hospital · Sites in China
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18+
Southeast University, China · Sites in China
Ages 18–80
Shanghai Zhongshan Hospital · Sites in China
Ages 20–90
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4 · Phase 4 2
First in 2009; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 258 is above the median of 115 across 276 interventional studies indexed under Pneumonia, Ventilator-Associated.
Median enrollment 174 across the 17 interventional studies, 200 across the 9 observational. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 26 have an industry lead sponsor. The 10 most frequent:
Affiliated Hospital of Nantong University is the lead sponsor of 97 studies on the registry; 57 are open to participants now.
Affiliated Hospital of Nantong University has 1 study filed under Pneumonia, Ventilator-Associated — fewer than ten, so there is no comparison to draw.
3 of the studies in Pneumonia, Ventilator-Associated with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06819462Southeast University, ChinaInhaled Colistin to Prevent Ventilator-Associated Pneumonia in Patients With Acute Brain Injury | 2026-12-31 |
| NCT07512596Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Study on the Safety and Efficacy of Polymyxin E2 Methanesulfonate for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia/Ventilator-Associated Bacterial Pneumonia Caused by Carbapenem-Resistant Gram-Negative Bacteria | 2027-07 |
| NCT07268560Sir Run Run Shaw HospitalReal-World Effectiveness of Aztreonam-Avibactam Against MBL-Producing CRE | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 26 studies in Pneumonia, Ventilator-Associated with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Research has shown that timely suctioning not only improves survival rates but also enhances the quality of life in ventilator-dependent patients. However, clinical judgment on the optimal timing for suctioning currently relies primarily on physician experience, lacking scientific evidence [10]. Airway viscous resistance reflects the frictional resistance encountered by gas flow within the airways and is closely associated with airway patency. When airway secretions increase, viscous resistance undergoes dynamic changes. Therefore, analyzing these dynamic variations in viscous resistance derived from ventilator waveforms to determine the optimal suctioning timing and assess its clinical impact on the progression of pulmonary inflammation holds significant scientific value and offers new insights and methodologies for clinical practice.
To validate the clinical feasibility and reliability of airway viscous resistance monitoring, explore the temporal correlation between inflammatory biomarkers and changes in airway viscous resistance, establish a reference threshold system for special populations, and provide experimental evidence for determining the optimal suctioning timing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigators will continuously monitor the airway viscous resistance of patients, and initiate suctioning when the airway viscous resistance increases by ≥6 cmH₂O.
Procedure: The dynamics of airway resistance · Diagnostic Test: conventional suctioning
In the control group, the decision to suction was made based on conventional clinical signs, including rhonchi and a rise in peak pressure.
Monitoring the dynamic changes in airway resistance in patients can be used to reflect the progression of pulmonary inflammation and determine the optimal timing for suctioning.
The timing for suctioning is determined based on clinical signs such as rhonchi and an elevated peak pressure.
The drop in airway viscous resistance before and after sputum suction
Airway viscous resistance drop (AVRD) is the primary efficacy endpoint of this study. It is defined as the difference in airway viscous resistance measured immediately before and after suctioning. Procedure: Record the ventilator-displayed viscous resistance value pre-suction; immediately after the maneuver, re-measure both viscous resistance and peak airway pressure with a high-precision pressure-time sensor. Calculation: The within-patient difference (pre minus post) is the AVRD. In a pilot study of nine patients, AVRD averaged 6.889 ± 3.551 cmH₂O, significantly larger than the concurrent peak-pressure drop (1.556 ± 1.740 cmH₂O), indicating that AVRD is more sensitive to the effect of suction on airway secretions. Clinical implication: AVRD can serve as a quantitative criterion for determining the optimal timing of endotracheal suction.
Time frame: the process of sputum aspiration(at most 30 minutes)
The number of participants with abnormal laboratory tests
Venous blood testing was performed, including a complete blood count (white blood cell count \[WBC\], neutrophil percentage \[NEUT%\]), C-reactive protein (CRP), and procalcitonin (PCT) to assess the systemic inflammatory status.
Time frame: Laboratory testing time ( at least 30 minutes)
Sputum bacterial culture
Sputum culture is performed to identify the source of infection and to diagnose VAP.
Time frame: 3 days
Plan to share: Yes — All data
Supporting information: Clinical study report
Time frame: From October 2025 until the end of the trial
Access criteria: Critical care researchers; all materials will be made available. Contact: Honglei Wu, e-mail: wu_honglei@163.com
Data sharing details ↗ · www.ahnmc.com
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Dec 2028, 38 months after the start.
Of 82 non-industry interventional studies with no phase under Pneumonia, Ventilator-Associated, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 36. This study's planned 38 months is above that.
Counting every sponsor, half of 83 studies reached it within 20 months; a quarter within 10 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pneumonia, Ventilator-Associated →
Affiliated Hospital of Nantong University